- Conditions
- Hereditary Hemorrhagic Telangiectasia
- Interventions
- ALN-6400, Placebo
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Cypress, California • Gainesville, Florida + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2665–2688
of 9,162
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis
- Interventions
- CABA-201
- Biological
- Lead sponsor
- Cabaletta Bio
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 21
- States / cities
- Orange, California • Sacramento, California • New Haven, Connecticut + 14 more
- Conditions
- COVID19
- Interventions
- COVID-19 convalescent plasma
- Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 9 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- PLN-74809, Placebo
- Drug
- Lead sponsor
- Pliant Therapeutics, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 79
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 69 more
- Conditions
- Lung Cancer, Non-Small Cell, Non-Small-Cell Lung Cancer
- Interventions
- Topotecan/Docetaxel combination, Docetaxel
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 399 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 67
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Tucson, Arizona + 59 more
- Conditions
- Validation Study
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Magrolimab, Venetoclax, Azacitidine, Cytarabine, Daunorubicin, Idarubicin, Steroidal Eye Drops
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Duarte, California • Los Angeles, California + 28 more
- Conditions
- Anemia, Aplastic
- Interventions
- Cyclophosphamide,Campath IH and TBI
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer
- Interventions
- RIsk-Reducing Salpingectomy (RRS), Risk-Reducing Oophorectomy-RRO, Risk-Reducing Salpingo-Oophorectomy-RRSO
- Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 11
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 6 more
- Conditions
- Chronic Spinal Cord Injury
- Interventions
- LIFT System
- Device
- Lead sponsor
- ONWARD Medical, Inc.
- Industry
- Eligibility
- 22 Years to 75 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 9
- States / cities
- Englewood, Colorado • Miami, Florida • Atlanta, Georgia + 6 more
- Conditions
- Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
- Interventions
- cytology specimen collection procedure, MEK 162 therapy or molecularly targeted therapy, therapeutic procedure, laboratory biomarker analysis, quality-of-life assessment
- Other · Drug · Procedure
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • New Haven, Connecticut • Jacksonville, Florida + 5 more
- Conditions
- Chronic Kidney Diseases, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes Mellitus, Diabetic Nephropathies
- Interventions
- Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion, Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions
- Drug
- Lead sponsor
- LaTonya J. Hickson
- Other
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Well-differentiated Non-functional NET of Thoracic Origin, Well-differentiated Non-functional NET of Gastrointestinal Origin, Well-differentiated Non-functional NET of Pancreatic Origin, Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
- Interventions
- PDR001
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 7
- States / cities
- Duarte, California • Denver, Colorado • Tampa, Florida + 4 more
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 468 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 14
- States / cities
- Iowa City, Iowa • Kansas City, Kansas • New Orleans, Louisiana + 11 more
- Conditions
- Age-Related Hearing Loss
- Interventions
- AUT00063, Placebo
- Drug
- Lead sponsor
- Autifony Therapeutics Limited
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 13
- States / cities
- Sacramento, California • Colorado Springs, Colorado • Boca Raton, Florida + 10 more
- Conditions
- Pancreatic Carcinoma, Pancreatic Neoplasm
- Interventions
- Biospecimen Collection, Distal Pancreatectomy, Lanreotide, Questionnaire Administration, Saline
- Procedure · Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 118
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 93 more
- Conditions
- Glioblastoma Multiforme
- Interventions
- IL13-PE38QQR, surgery and catheter placement (2 procedures), prolifespan 20 with carmustine implant (GLIADEL® Wafer), surgery and wafer placement (1 procedure)
- Drug · Procedure
- Lead sponsor
- INSYS Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Duarte, California • Los Angeles, California + 30 more
- Conditions
- Dermatitis, Atopic
- Interventions
- Abrocitinib 100 mg, Abrocitinib 200 mg, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 3,166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 156
- States / cities
- Birmingham, Alabama • Anaheim, California • Encinitas, California + 101 more
- Conditions
- Deep Vein Thrombosis
- Interventions
- Pneumatic SCD - VenaFlow System (DJO Global)
- Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Chronic Kidney Diseases
- Interventions
- Allogeneic adipose-derived mesenchymal stem cells (MSC)
- Drug
- Lead sponsor
- LaTonya J. Hickson
- Other
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Multiple Myeloma
- Interventions
- MyHOPE™ for Multiple Myeloma, MyHope HCP Portal
- Device
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 34
- States / cities
- Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 27 more
- Conditions
- Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Primary Peritoneal Cavity Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Primary Peritoneal Cavity Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Primary Peritoneal Cavity Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cavity Cancer
- Interventions
- cisplatin, alvocidib, cisplatin/flavopiridol
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Hodgkin Lymphoma
- Interventions
- PLX3397
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Chicago, Illinois • Rochester, Minnesota + 3 more
- Conditions
- Lymphoma
- Interventions
- rituximab, cyclophosphamide, doxorubicin hydrochloride, everolimus, prednisone, vincristine sulfate
- Biological · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota